Leonard Calabrese

Leonard Calabrese's AcademicInfluence.com Rankings

Leonard Calabrese

Philosophy

#5161

World Rank

#7893

Historical Rank

Logic

#2619

World Rank

#3635

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Leonard Calabrese's Degrees

Doctorate Medicine Case Western Reserve University

Why Is Leonard Calabrese Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Leonard Calabrese is an American rheumatologist, an osteopathic physician, and an internationally recognized HIV/AIDS and hepatitis C researcher at the Cleveland Clinic. Calabrese is the vice chair of the Cleveland Clinic's Department of Rheumatic and Immunologic Diseases and the co-director of the Center for Vasculitis Care and Research, while also serving as director of the Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology. He is also a medical professor at the Cleveland Clinic Lerner College of Medicine. Over the course of his academic research career, Calabrese has authored more than 300 publications including book chapters and peer-reviewed journal articles.

(See a Problem?)

Leonard Calabrese's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. (2010) (2232)
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). (2010) (1997)
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. (2010) (1952)
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. (2010) (1862)
The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. (2010) (969)
Narrative Review: Reversible Cerebral Vasoconstriction Syndromes (2007) (814)
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. (2010) (796)
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. (2010) (621)
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. (2010) (569)
Primary Angiitis of the Central Nervous System: REPORT OF 8 NEW CASES, REVIEW OF THE LITERATURE, AND PROPOSAL FOR DIAGNOSTIC CRITERIA (1988) (564)
Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. (2011) (517)
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. (2002) (503)
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). (2001) (416)
Thalidomide: current and potential clinical applications. (2000) (306)
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. (2011) (285)
IL-6 biology: implications for clinical targeting in rheumatic disease (2014) (278)
Primary angiitis of the CNS (2011) (268)
The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. (2004) (262)
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. (2010) (250)
The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. (2010) (246)
Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. (1992) (241)
The role of IL-6 in host defence against infections: immunobiology and clinical implications (2017) (238)
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination (2021) (238)
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection (2004) (218)
High-Resolution MRI Vessel Wall Imaging: Spatial and Temporal Patterns of Reversible Cerebral Vasoconstriction Syndrome and Central Nervous System Vasculitis (2014) (218)
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies (2006) (216)
Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. (2009) (203)
Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. (1992) (196)
Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. (2002) (194)
Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing (2018) (189)
Vasculitis in the central nervous system. (1997) (188)
Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. (2012) (181)
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. (2007) (179)
Induction of Clinical Autoimmune Disease by Therapeutic Interferon-α (2003) (177)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). (2018) (173)
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout (2014) (173)
Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. (1995) (167)
Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity (2017) (163)
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis (2010) (159)
Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. (2005) (159)
Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection (2007) (154)
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. (2004) (149)
Benign angiopathy: a distinct subset of angiographically defined primary angiitis of the central nervous system. (1993) (145)
Autoimmune Reactivity in Meniere'S Disease: A Preliminary Report (1983) (134)
Moving towards personalized treatments of immune-related adverse events (2020) (132)
Rheumatic immune-related adverse events from cancer immunotherapy (2018) (132)
Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. (2007) (131)
Systemic vasculitis in association with human immunodeficiency virus infection. (1989) (131)
Menstrual Abnormalities, Nutritional Patterns, and Body Composition in Female Classical Ballet Dancers. (1983) (130)
Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? (2008) (125)
Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. (1987) (125)
Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. (1995) (120)
Molecular differences in anticytokine therapies. (2003) (114)
Practical versus theoretical management of autoimmune inner ear disease (1984) (113)
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. (2016) (112)
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors (2020) (112)
Diagnosis and classification of central nervous system vasculitis. (2014) (112)
The rheumatic manifestations of infection with the human immunodeficiency virus. (1989) (108)
Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. (2003) (107)
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. (2002) (104)
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance (2015) (102)
The effects of rituximab on immunocompetency in patients with autoimmune disease. (2008) (101)
Clinical diagnosis of immune inner‐ear disease (1988) (100)
Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. (2002) (100)
Tumour-like mass lesion: an under-recognised presentation of primary angiitis of the central nervous system (2008) (99)
Altered central nervous system signal during motor performance in chronic fatigue syndrome (2004) (95)
Vasculitis and infection with the human immunodeficiency virus. (1991) (94)
Infections and systemic vasculitis. (1998) (94)
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis (2010) (94)
Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies (2008) (92)
Herpes zoster ophthalmicus and acquired immune deficiency syndrome. (1984) (85)
Placebo-controlled trial of prednisone in advanced HIV-1 infection (2001) (85)
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials (2013) (81)
Inclusion body myositis presenting as treatment-resistant polymyositis. (1987) (80)
Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations (2008) (80)
Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. (1993) (78)
The pathophysiology of HCV induced B-cell clonal disorders. (2007) (78)
Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. (2005) (77)
Autoimmune reactivity in Cogan's syndrome: A preliminary report (1983) (77)
Central nervous system vasculitis (2009) (75)
T cell receptor peptide vaccination in rheumatoid arthritis : A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides (1998) (73)
Drug‐induced vasculitis (1996) (73)
Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash. (1987) (69)
Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis (2017) (68)
Management of rheumatic disease with comorbid HBV or HCV infection (2012) (66)
Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections (2007) (66)
Vasculitis. A collection of pearls and myths. (2007) (65)
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases (2016) (65)
Correlates and Changes in Empathy and Attitudes Toward Interprofessional Collaboration in Osteopathic Medical Students (2013) (61)
Nutritional and medical considerations in dancers. (1983) (61)
Long-term outcomes after reversible cerebral vasoconstriction syndrome (2016) (61)
Rheumatic manifestations of hepatitis C infection (2003) (59)
Rheumatic symptoms and human immunodeficiency virus infection. The influence of clinical and laboratory variables in a longitudinal cohort study. (1991) (59)
Autoimmune Endolymphatic Hydrops: Five-Year Review (1988) (59)
Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. (2002) (58)
Physiological aspects of dance. (1983) (57)
Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers (2004) (57)
The effects of anabolic steroids and strength training on the human immune response. (1989) (56)
Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases (2012) (54)
Neurologic manifestations of systemic vasculitides. (1994) (54)
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature (2019) (54)
Cycling CD4+ T cells in HIV-infected immune nonresponders have mitochondrial dysfunction (2018) (53)
Therapy: Targeted but not trouble-free: efalizumab and PML (2009) (52)
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). (2019) (52)
Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? (2009) (52)
Evaluation and treatment of central nervous system vasculitis (1995) (50)
Methotrexate in the treatment of rheumatoid arthritis; pilot study. (1980) (49)
Multifocal varicella-zoster virus vasculopathy without rash. (2003) (49)
Dietary influences on cardiovascular disease risk in anabolic steroid-using and nonusing bodybuilders. (1989) (48)
Vasculitis: determinants of disease patterns (2014) (48)
Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder. (2016) (48)
The pulmonary manifestations of systemic lupus erythematosus. (1985) (47)
Predictive value of laboratory tests in “autoimmune” inner ear disease: preliminary report (1986) (47)
Rheumatoid arthritis complicated by infection with the human immunodeficiency virus and the development of Sjögren's syndrome. (1989) (46)
Autoimmune manifestations of human immunodeficiency virus (HIV) infection. (1988) (46)
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review (2021) (46)
Development of antinuclear antibodies during acebutolol therapy (1979) (45)
Nutritional and medical aspects of gymnastics. (1985) (44)
Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection (2016) (44)
Primary angiitis of the central nervous system. (2013) (44)
Microsporidial keratoconjunctivitis caused by Septata intestinalis in a patient with acquired immunodeficiency syndrome. (1996) (44)
Sorting out the risks in progressive multifocal leukoencephalopathy (2015) (44)
Weighted criteria for the diagnosis of systemic lupus erythematosus. (1984) (43)
Development of systemic lupus erythematosus after thymectomy for myasthenia gravis. Studies of suppressor cell function. (1981) (41)
Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome. (1993) (40)
Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). (2014) (39)
Extrahepatic immunological complications of hepatitis C virus infection. (2005) (39)
Inclusion body myositis: analysis of 32 cases. (1992) (39)
Emerging viral infections and arthritis: the role of the rheumatologist (2008) (38)
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management. (2017) (37)
Central nervous system vasculitis in Behçet's syndrome: angiographic improvement after therapy with cytotoxic agents. (1989) (37)
Vasculitis of the central nervous system. (1995) (37)
CNS Vasculitis: an Approach to Differential Diagnosis and Management (2018) (36)
Dysphagia in patients with inclusion body myositis (1998) (36)
Thalidomide revisited: pharmacology and clinical applications. (1998) (35)
Granulomatous angiitis of the nervous system. (1997) (35)
Benign angiopathy of the central nervous system presenting with intracerebral hemorrhage. (2007) (35)
The frequency of low muscle mass and its overlap with low bone mineral density and lipodystrophy in individuals with HIV--a pilot study using DXA total body composition analysis. (2012) (35)
Cytokine storm and the prospects for immunotherapy with COVID-19. (2020) (35)
Lupus-Related Hepatitis: Complication of Lupus or Autoimmune Association? Case Report and Review of the Literature (2006) (35)
Placebo‐Controlled Trial of Cyclosporin‐A in HIV‐1 Disease: Implications for Solid Organ Transplantation (2002) (34)
Diagnosis and treatment of cutaneous leukocytoclastic vasculitis (2013) (34)
Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2009) (34)
The A, B, Cs of viral hepatitis in the biologic era (2010) (34)
Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. (2010) (34)
Human Immunodeficiency Virus Infection, Exercise and Athletics (1993) (34)
The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy (2017) (33)
Anakinra Treatment of Patients with Rheumatoid Arthritis (2002) (33)
Pilot study to assess the frequency of fibromyalgia, depression, and sleep disorders in patients with granulomatosis with polyangiitis (Wegener's) (2011) (32)
Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. (2002) (32)
Plasmapheresis therapy of immunologic disease. Report of nine cases and review of the literature. (1980) (31)
Chronic fatigue syndrome and a disorder resembling Sjögren's syndrome: preliminary report. (1994) (31)
Physicians' attitudes, beliefs, and practices regarding AIDS health care promotion. (1991) (29)
T cell lymphoma occurring in Sjögren's syndrome. (1984) (29)
Acute calcific tendinitis of the hip: case report with magnetic resonance imaging findings. (1997) (28)
Comparison of interferon-{gamma} release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study (2010) (28)
Immunology and exercise. Physiology, pathophysiology, and implications for HIV infection. (1994) (28)
Let the fog be lifted: screening for hepatitis B virus before biological therapy (2011) (27)
Deficiency of T cell mediated regulation of anti-DNA production in systemic lupus erythematosus. (1980) (27)
SARS CoV-2 infection among patients using immunomodulatory therapies (2020) (27)
Autoimmune vestibular dysfunction: Preliminary report (1985) (26)
Therapy of resistant systemic necrotizing vasculitis. Polyarteritis, Churg-Strauss syndrome, Wegener's granulomatosis, and hypersensitivity vasculitis group disorders. (1995) (26)
A rational approach to PML for the clinician (2011) (26)
Familial late complement component (C6, C7) deficiency with chronic meningococcemia. (1980) (25)
Reversible cerebral vasoconstriction syndrome: Is it more than just cerebral vasoconstriction? (2015) (25)
Infection with the human immunodeficiency virus type 1 and vascular inflammatory disease. (2004) (25)
Persistence of high risk sexual activity among homosexual men in an area of low incidence for acquired immunodeficiency syndrome. (1986) (25)
Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases (2017) (25)
Tuberculosis of the greater trochanteric bursa. (1983) (25)
Therapy: Rituximab and PML risk—informed decisions needed! (2009) (25)
Primary central nervous system vasculitis: progress and questions (2007) (24)
Practical aspects of targeting IL-6 in COVID-19 disease. (2020) (23)
Two unusual strains of Candida arthritis. (1984) (23)
Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association (2017) (23)
The connection between chronic fatigue syndrome and neurally mediated hypotension. (1998) (23)
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study (2020) (23)
Human immunodeficiency virus (HIV) infection and arthritis. (1993) (23)
Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with transfer factor. (1987) (22)
SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction. (2016) (22)
Diagnostic strategies in vasculitis affecting the central nervous system. (2002) (21)
Therapy of systemic vasculitis. (1997) (21)
Neutrophilic myositis: an extra-intestinal manifestation of ulcerative colitis. (2002) (20)
Transmission of HTLV-III infection from man to woman to man. (1986) (20)
Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout (2017) (20)
Primary angiitis of the central nervous system: the penumbra of vasculitis. (2001) (19)
Preventing Hepatitis B reactivation in immunosuppressed patients: Is it time to revisit the guidelines? (2010) (19)
Response of immunoregulatory lymphocyte subsets to methotrexate in rheumatoid arthritis. (1990) (19)
The yin and yang of tumor necrosis factor inhibitors. (2006) (19)
Lack of correlation between promiscuity and seropositivity to HTLV-III from a low-incidence area for AIDS. (1985) (18)
Exercise, immunity, and infection (1996) (18)
Interferon therapy for COVID-19 and emerging infections: Prospects and concerns. (2020) (18)
Maintenance of CD4+ cells by thymopentin in asymptomatic HIV‐infected subjects: results of a double‐blind, placebo‐controlled study (1992) (18)
Type I interferon, anti-interferon antibodies, and COVID-19 (2021) (17)
Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. (2003) (17)
Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms (2019) (17)
Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? (2019) (16)
The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding? (2021) (16)
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. (2021) (16)
Serum beta 2-microglobulin and interferon in homosexual males: relationship to clinical findings and serologic status to the human T lymphotropic virus (HTLV-III). (1984) (16)
The Use of Nonsteroidal Anti-inflammatory Drugs in Sports. (1986) (16)
Opportunistic infections in patients with ectopic ACTH-secreting tumors. (1982) (15)
Baricitinib and dexamethasone for hospitalized patients with COVID-19. (2021) (15)
For patients with rheumatic disease and hepatitis C infection: the end of interferon (2015) (15)
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. (2020) (15)
Intravenous immunoglobulin in rheumatic disease. (1996) (15)
Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. (2011) (15)
The Microbiome of Temporal Arteries (2019) (14)
THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (14)
T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. (1998) (14)
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity (2022) (14)
Changing patterns of morbidity and mortality in HIV disease. (2001) (13)
Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV (2013) (13)
The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al (2016) (13)
Breakthrough SARS‐CoV‐2 infections in immune mediated disease patients undergoing B cell depleting therapy: A retrospective cohort analysis (2022) (13)
The role of thalidomide in the treatment of rheumatic disease. (2000) (13)
Chronic fatigue syndrome. (1992) (13)
Physician Empathy Is Not Associated with Laboratory Outcomes in Diabetes: a Cross-sectional Study (2018) (12)
Clinical management issues in vasculitis. Angiographically defined angiitis of the central nervous system: diagnostic and therapeutic dilemmas. (2003) (12)
Rheumatology and COVID-19 at 1 year: facing the unknowns (2021) (12)
HIV and Sports: What Is the Risk? (1993) (12)
Safety of Recombinant Zoster Vaccine: a Retrospective Study of 622 Rheumatology Patients. (2021) (12)
Henoch-Schönlein purpura associated with anti-Ro (SSA) and antiphospholipid antibody syndrome. (1993) (12)
The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al (2016) (12)
Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis (2019) (12)
Inclusion body myositis. (1994) (12)
Rates of Serious Infections in HIV‐Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases (2016) (11)
Commentaries on Viewpoint: Muscle atrophy is not always sarcopenia. (2012) (11)
Emerging viral infections in rheumatic diseases. (2011) (11)
Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1. (2020) (11)
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. (2019) (11)
Musculoskeletal manifestations of Addison's disease. (1979) (11)
Biologic agents and liver toxicity: an added concern or therapeutic opportunity? (2007) (10)
Hearing and Sjögren's Syndrome (1996) (10)
Primary Central Nervous System Vasculitis (2012) (10)
Rheumatic manifestations of HIV infection. (1993) (10)
Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition. (2020) (10)
Immune Reactivity in Bell's Palsy (1986) (10)
Treatment of psoriasis with ustekinumab in a patient with HIV‐related Kaposi sarcoma (2019) (9)
Reflex sympathetic dystrophy syndrome complicating polymyalgia rheumatica. (1981) (9)
Lymphocytic vasculitis presenting as diffuse subcutaneous edema after hepatitis B virus vaccine. (1997) (9)
Results of a Phase II Rheumatoid Arthritis Clinical Trial Using T-Cell Receptor Peptides (1999) (9)
Histocompatibility antigens and rheumatic diseases. (1978) (9)
Central nervous system vasculitis in the intensive care unit. (2002) (8)
Glycoforms of α1-Acid Glycoprotein in Sera of Human Immunodeficiency Virus-Infected Persons (1994) (8)
The treatment of vasculitis of the central nervous system. (1987) (8)
THU0218 INCIDENCE AND RISK FACTORS FOR HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING UPADACITINIB (2020) (8)
Limited plasmapheresis in fulminant leukocytoclastic vasculitis. (1982) (8)
Concordance of angiography and cerebral biopsy results for suspected primary central nervous system vasculitis: A multi-center retrospective review (2019) (8)
HIV update 2005: origins, issues, prospects, and complications. (2005) (8)
Vascular nodules and plaques resembling chronic mucocutaneous candidiasis in a patient with a low interleukin 2 level. (1993) (8)
Progression of autoimmune thyroiditis in an HIV-infected woman on HAART. (1999) (7)
Metagenomics for chronic meningitis: clarifying interpretation and diagnosis (2017) (7)
Rapid progression of HIV-1 infection to AIDS. (1992) (7)
Role of Natural Autoantibodies in Ugandans With Rheumatic Heart Disease and HIV☆ (2016) (7)
Rheumatologic manifestations of HIV-1 and HTLV-1 infections. (1998) (7)
Sorting Out the Complexities of Autoimmunity and Checkpoint Inhibitors: Not So Easy (2018) (7)
THU0197 SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS (2020) (7)
Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. (2020) (7)
AIDS update 1999: viral reservoirs and immune-based therapies. (1999) (6)
Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications (2020) (6)
The INTERnational Study on Primary Angiitis of the CEntral Nervous System – A Call to the World (2014) (6)
Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency (2020) (6)
Commentary and update: serological tests for diagnosis of systemic lupus erythematosus (SLE). (1983) (6)
Infections in the Era of Targeted Therapies: Mapping the Road Ahead (2020) (6)
Why Mindfulness/Meditation Is a “No-Brainer” for Health-Care Professionals (2018) (6)
A common-sense approach to chronic fatigue in primary care. (1999) (6)
Rheumatoid arthritis and primary care: The case for early diagnosis and treatment (1999) (5)
Branch retinal artery occlusions as the presenting feature of primary central nervous system vasculitis. (2004) (5)
Cryoglobulinemic vasculitis and lymphocytic interstitial pneumonitis in a person with HIV infection. (2005) (5)
Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial. (1995) (5)
Long-term outcomes of patients with primary angiitis of the central nervous system. (2019) (5)
Sir William Osler Then and Now: Thoughts for the Osteopathic Profession (2005) (5)
Primary angiitis of the central nervous system: reflections on 20 years of investigation. (2009) (5)
Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis (2013) (4)
Central nervous system vasculitis: advances in diagnosis. (2019) (4)
Urticaria, nephritis, and pseudotumor cerebri. (1990) (4)
Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF. (2020) (4)
Risk factors for HIV infection in homosexual men: the Cleveland men's study of risks in a low-prevalence area. (1992) (4)
Fulminating vasculitis in a homozygous C2-deficient patient. (1985) (4)
Reversible Cerebral Vasoconstriction Syndrome (2009) (4)
Menstrual abnormalities and body composition in professional female ballet dancers (1982) (4)
The ANA profile: quality and cost-effective laboratory utilization. (1989) (4)
FRI0141 CHARACTERIZATION OF SERIOUS INFECTIONS WITH UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS (2020) (4)
Indeterminate reactors to tests for human immunodeficiency virus (HIV) (1989) (4)
Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications (2022) (4)
Central Nervous System Vasculitis Complicating Rheumatoid Arthritis in a Patient on a TNF Inhibitor: a Causal Association? Case Report and Systematic Review (2016) (4)
Should I order an anti-CCP antibody test to diagnose rheumatoid arthritis? (2012) (4)
Differentiation between neurosarcoidosis and primary central nervous system vasculitis based on demographic, cerebrospinal and imaging features. (2020) (4)
Thalidomide's tightly controlled "comeback". (1999) (4)
Cutaneous vasculitis, hypersensitivity vasculitis, erythema nodosum, and pyoderma gangrenosum. (1990) (4)
THU0649 PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (4)
132. COMORBID VASCULITIS AMONG PATIENTS IN A NATIONAL PRIMARY IMMUNODEFICIENCY DATABASE (2019) (3)
MBDA: A Valuable Tool for Medical Decision Making (2019) (3)
FP27-TU-04 Reversible cerebral vasoconstriction syndromes (RCVS) - two center experience of 139 cases (2009) (3)
Recognizing Rheumatologic Aspects of Cocaine Abuse (2012) (3)
Methotrexate and rheumatoid arthritis. (1989) (3)
2015 American College of Rheumatology Guidelines for the Treatment of Rheumatoid Arthritis – Hepatitis B (HBV) Screening (2016) (3)
β2-Microglobulin and the Acquired Immunodeficiency Syndrome in a Low-Incidence Area (1985) (3)
A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA). (2000) (3)
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases (2023) (3)
Exercise, infection and rheumatic diseases: what do we know? (2021) (3)
AMSSM position statement update: blood-borne pathogens in the context of sports participation (2019) (3)
A headache and a mass lesion: vasculitis or CNS sarcoid? (2003) (3)
Proceedings of the 5th annual perspectives in rheumatic diseases. (2013) (3)
Viral arthritis. (2005) (3)
Infection and Malignancy in Rheumatic Diseases. (2017) (3)
Empathy: A Vital Sign for the Osteopathic Medical Profession (2016) (3)
AIDS and Athletes. (1989) (3)
OP0165 EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY (2019) (3)
Autoimmunity in otology. (1986) (2)
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases (2023) (2)
Granulomatous angiitis and the pituitary gland. (1985) (2)
Virus-Associated Vasculitides:Clinical Aspects (2000) (2)
Allogeneic suppression of polyclonal immunoglobulin production in normals and patients with systemic lupus erythematosus. (1980) (2)
Reply to ‘Personalized treatment of immune-related adverse events — balance is required’ (2020) (2)
110 – Rheumatologic aspects of viral infections (2015) (2)
Nitrogen mustard as induction therapy for rheumatoid arthritis: clinical and immunologic effects. (1992) (2)
310: THE EFFECT OF ANABOLIC STEROIDS ON THE IMMUNE RESPONSE IN MALE BODY. BUILDERS (1987) (2)
ChronicMeningitis Investigated viaMetagenomic Next-Generation Sequencing (2018) (2)
Vasculitis as a major morbidity factor in patients with hypomorphic RAG mutations: 350 (2019) (2)
Epidemiologic and laboratory evaluation of homosexual males from an area of low incidence for acquired immunodeficiency syndrome (AIDS). (1986) (2)
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. (2021) (2)
Glycoforms of alpha 1-acid glycoprotein in sera of human immunodeficiency virus-infected persons. (1994) (2)
The physician's role in the prevention of AIDS. (1988) (2)
Cutaneous vasculitis, hypersensitivity vasculitis, erythema nodosum, and pyoderma gangrenosum. (1990) (2)
Comment on the article by Furst and Kremer (1989) (2)
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Comment on the Article by Crickx et al (2016) (1)
183. MICROBIOME IN AORTITIS (2019) (1)
Methotrexate (MTX) failed to control giant cell arteritis (GCA) (2001) (1)
"Possible" primary Sjögren's syndrome with diffuse cerebrovasculitis and lymphocytic interstitial pneumonitis. (1987) (1)
Performing arts rheumatology. (1995) (1)
Case report. Irreversible chronic renal failure following jejunoileal bypass. (1980) (1)
OP0184 The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate (2018) (1)
Reflections on rheumatological aspects of COVID-19 (2020) (1)
The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. (2020) (1)
Serial vessel wall enhancement pattern on high-resolution vessel wall magnetic resonance imaging and clinical implications in patients with central nervous system vasculitis. (2022) (1)
Abstract WMP55: Vessel Wall Characteristics using High Resolution Magnetic Resonance Imaging in Reversible Cerebral Vasoconstriction Syndrome and Central Nervous System Vasculitis (2013) (1)
Hypersensitivity vasculitis group (HVG). A case-oriented review of a continuing clinical spectrum. (1982) (1)
Hepatitis C: Health-related quality of life, rheumatologic, virologic and histologic outcomes (1998) (1)
P1_168 Differentiation Between Neurosarcoidosis and Primary CNS Vasculitis Based on Clinical and Cerebrospinal Fluid Parameters (2017) (1)
Dermatomyositis and malignancy: A proposal for evidence-based malignancy screening guidelines: 2800 (2016) (1)
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting (2021) (1)
Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndromes (2009) (1)
Reply to Barrett, et al. (2016) (1)
HCV Treatments and Their Integration Into Rheumatology (2015) (1)
Editorial: Reflections on rheumatological aspects of COVID-19 (2020) (1)
OP0003 Rheumatic immune related adverse events of checkpoint therapy for cancer: case series of an emerging nosologic entity (2017) (1)
Chronic fatigue and immune dysfunction. (1992) (1)
Differential diagnosis of hypersensitivity vasculitis. (1990) (1)
Presentation to HIV care and antiretroviral therapy initiation and response in clinical practice from 2003 through 2013 (2019) (1)
Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)? (2022) (1)
Long-term outcomes of patients with Reversible Cerebral Vasoconstriction Syndrome (RCVS) (2013) (1)
Human immunodeficiency virus and the rheumatologist. (1996) (1)
Evolving treatment paradigms for rheumatoid arthritis: Translating comprehensive patient evaluations into personalized therapy. (2020) (1)
HIV update 2002: delaying treatment to curb rising resistance. (2002) (1)
Polyarteritis nodosa diagnosed by endoscopic polypectomy. (1980) (1)
L36. Evidence-based clinical science and art in the diagnosis of central nervous system vasculitis. (2013) (1)
Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy (2022) (0)
Orthotopic heart transplantation in eosinophilic granulomatosis with polyangiitis (2013) (0)
Proceedings of the 2013 Rheumatology Winter Clinical Symposia. (2013) (0)
Real risks of HIV transmission to physicians and their staffs (1992) (0)
FRI0494 RHEUMATIC IMMUNE RELATED ADVERSE EVENTS OF CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW OF 70 PATIENTS (2020) (0)
Evidence for Alternative Complement Cascade Activation in Primary CNS Vasculitis (2018) (0)
Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review. (2022) (0)
IL-6 blockade with tocilizumab diminishes indices of inflammation that are linked to mortality in treated HIV infection. (2023) (0)
Modulation of T-cell-mediated regulation of antibody production by interaction with specific immune complexes. (1988) (0)
NSAIDs questionable as first-line therapy for rheumatic conditions in the elderly (1994) (0)
Epidemiologie and laboratory evaluation of homosexualmales f r om an area of low incidence f or acquired immunodeficiency syndrome (AIDS) 1 (2013) (0)
New HIV series helps to define osteopathic physicians' role in AIDS epidemic. (1992) (0)
Clinical characteristics, brain magnetic resonance imaging findings and diagnostic approach of the primary central nervous system vasculitis according to angiographic classification. (2022) (0)
Abstract 11546: Role of Natural Autoantibodies Among Ugandans With Rheumatic Heart Disease and HIV (2015) (0)
Questions and answers. What are safe and practical exercises for someone with arthritis? (2000) (0)
Genitourinary Pain and Inflammation in Rheumatic Diseases (2008) (0)
Rheumatologie manifestations of HIV'l and HTLV-I infections (2013) (0)
AIDS and osteopathic medical education. (1989) (0)
Simple guidelines for HIV testing in the physician's practice. (1992) (0)
Chapter-35 Primary Angiitis of Central Nervous System (2015) (0)
Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles (2021) (0)
SP0074 DIAGNOSIS OF CEREBRAL VASCULITIS (2019) (0)
248. RITUXIMAB VERSUS CYCLOPHOSPHAMIDE FOR VASCULITIC NEUROPATHY: A PATIENT REPORTED OUTCOMES STUDY (2019) (0)
Establishment of a Registry To Identify Cases of PML Using Uniform Diagnostic Criteria (S08.002) (2012) (0)
Arteriovenous malformation of the brain mimicking primary central nervous system vasculitis (2008) (0)
Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy (2021) (0)
174. VASCULITIS AS A MAJOR MORBIDITY FACTOR IN PATIENTS WITH HYPOMORPHIC RAG VARIANTS (2019) (0)
Abstract T P172: Putative Blood Biomarkers for Reversible Cerebral Vasoconstriction Syndrome (2014) (0)
Vasculitis and chronic persistent viral infections. (1998) (0)
309: RELATIONSHIP OF ANABOLIC STEROID INTAKE TO BODY COMPOSITION OF BODY BUILDERS (1987) (0)
Suppressor Function in Immunologic Deficiency States (2018) (0)
always sarcopenia Commentaries on Viewpoint: Muscle atrophy is not (2012) (0)
Long COVID: defining the role of rheumatology in care and research (2022) (0)
The family physician's contribution to the care of patients in the final stages of HIV infection. (1992) (0)
HIV May Be a Cause of Musculoskeletal Syndromes (1989) (0)
Hypersensitivity vasculitis group (HVG) (2013) (0)
Using viral load, CD4+ levels, and clinical response to guide antiviral therapy for HIV. (2000) (0)
Can numerical rating scales of disease impact be used as targets for patient-centred management in rheumatoid arthritis? (2022) (0)
The physician's role in a community-based effort against the AIDS epidemic. (1987) (0)
The association of lupus anticoagulant and anti-DNA binding in patients with systemic lupus erythematosus. (1985) (0)
AMSSM Position Statement Update: Blood-Borne Pathogens in the Context of Sports Participation. (2019) (0)
NEW AGENTS FOR RHEUMATOID ARTHRITIS (2013) (0)
Article Commentary: HIV, AIDS, and the Performing Arts (1998) (0)
Virus‐Associated Vasculitides (2012) (0)
The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era (2022) (0)
Human immunodeficiency virus infection and rheumatic disease. (1997) (0)
Adult primary angiitis of the central nervous system and related syndromes (2014) (0)
Bone Marrow Aspiration and Biopsy in Hiv Infection (1992) (0)
Simple guidelines for HIV testing in the physician's practice (1992) (0)
SAT0220 Evaluation of live zoster vaccine in a subset of patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, and adalimumab with methotrexate: results from a phase 3b/4 randomised trial (2018) (0)
Real risks of HIV transmission to physicians and their staffs. American Osteopathic Association Task Force on AIDS. (1992) (0)
New HIV series helps to define osteopathic physicians' role in AIDS epidemic (1992) (0)
Long-Term Stroke and Headache Outcomes in Reversible Cerebral Vasoconstriction Syndrome (RCVS) (P05.236) (2013) (0)
AIDS: a challenge for osteopathic physicians. (1988) (0)
The physician's role in the prevention of AIDS (1988) (0)
Image in Cardiology. Takayasu arteritis. (2003) (0)
Clues for suspecting a patient is infected with the HIV (1992) (0)
New Developments in the Treatment of Psoriatic Arthritis : Clinical Updates From London (2016) (0)
Diagnosis of systemic lupus erythematosus. The value of immunologic tests. (1984) (0)
Sorting out cutaneous vasculitis--a rheumatologist's perspective. (2000) (0)
Angiographically defined primary angiitis of the CNS: is it really benign? (1999) (0)
Primary angiitis of the CNS and its mimics (2010) (0)
Progressive multifocal leukoencephalopathy in the biologic era: implications for practice. Introduction. (2011) (0)
AIDS: current achievement, future problems. (1985) (0)
Glucocorticoids in Rheumatoid Arthritis (RA): Advances in Balancing Risks and Benefits (2010) (0)
The New and Evolving Science of IL-6 in Rheumatoid Arthritis Neutrophils in RA and the Role of IL-6 (2017) (0)
Treatment of SLE: bridging the gap from clinical trials to the clinic - a meeting report (2013) (0)
Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV (2022) (0)
ATHLETESʼ BEHAVIOR, KNOWLEDGE, ATTITUDES AND FEARS REGARDING HIV INFECTION AND TRANSMISSION: 412 (1995) (0)
THU0567 POLYMYALGIA RHEUMATICA-LIKE SYNDROME FROM CHECKPOINT INHIBITOR THERAPY: CASE SERIES AND SYSTEMATIC REVIEW OF THE LITERATURE (2019) (0)
184. THE MICROBIOME OF TEMPORAL ARTERIES (2019) (0)
1122 THE AMERICAN COLLEGE OF RHEUMATOLOGY 1990 CRITERIA FOR THE CLASSIFICATION OF GIANT CELL ARTERITIS (2010) (0)
The clinical picture. An expanding skin lesion in a patient on immunosuppressive therapy. (2006) (0)
Rheumatologic immune-related adverse events (irAE) in patients (pts) with genitourinary (GU) malignancies treated with immune checkpoint inhibitors (CPI). (2018) (0)

This paper list is powered by the following services:

Other Resources About Leonard Calabrese

en.wikipedia.org

What Schools Are Affiliated With Leonard Calabrese?

Leonard Calabrese is affiliated with the following schools:

Leonard Calabrese's Academic­Influence.com Rankings